



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

**Policy #** 00110

**Original Effective Date:** 02/23/2004

**Current Effective Date:** 10/16/2013

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

### **When Services Are Eligible for Coverage**

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider the use of radioembolization (RE) to treat primary hepatocellular carcinoma (HCC) that is unresectable and limited to the liver to be **eligible for coverage**.

Based on review of available data, the Company may consider the use of radioembolization (RE) in primary hepatocellular carcinoma (HCC) as a bridge to liver transplantation to be **eligible for coverage**.

Based on review of available data, the Company may consider the use of radioembolization (RE) to treat hepatic metastases from neuroendocrine tumors (carcinoid and noncarcinoid) with diffuse and symptomatic disease when systemic therapy has failed to control symptoms to be **eligible for coverage**.

Based on review of available data, the Company may consider the use of radioembolization (RE) to treat unresectable hepatic metastases from colorectal cancer (CRC) that are both progressive and diffuse, in patients with liver-dominant disease who are refractory to chemotherapy or are not candidates for chemotherapy to be **eligible for coverage**.

### **When Services Are Considered Investigational**

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

Based on review of available data, the Company considers radioembolization (RE) for all other hepatic metastases except as noted above to be **investigational**.\*

Based on review of available data, the Company considers radioembolization (RE) to treat primary intrahepatic cholangiocarcinoma (ICC) to be **investigational**.\*

### **Background/Overview**

Hepatic tumors can arise either as primary liver cancer or by metastasis to the liver from other organs. Local therapy by surgical resection with tumor-free margins or liver transplantation is the only potentially curative treatments. Unfortunately, most hepatic tumors are unresectable at diagnosis, due either to their



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

anatomic location, size, number of lesions, concurrent nonmalignant liver disease, or insufficient hepatic reserve.

The use of external beam radiotherapy (EBRT) and the application of more advanced radiotherapy approaches (e.g., intensity-modulated radiotherapy [IMRT]) may be of limited use in patients with diffuse, multiple lesions due to the low tolerance of normal liver to radiation compared to the higher doses of radiation needed to kill the tumor.

Various nonsurgical ablative techniques have been investigated that seek to cure or palliate unresectable hepatic tumors by improving locoregional control. These techniques rely on extreme temperature changes, particle and wave physics (microwave or laser ablation), or arterial embolization therapy including chemoembolization, bland embolization, or RE.

Radioembolization, referred to as selective internal radiation therapy or "SIRT" in older literature, is the intra-arterial delivery of small beads (microspheres) impregnated with yttrium-90 via the hepatic artery. The microspheres, which become permanently embedded, are delivered to tumor preferentially to normal liver, as the hepatic circulation is uniquely organized, whereby tumors greater than 0.5cm rely on the hepatic artery for blood supply while normal liver is primarily perfused via the portal vein. Yttrium-90 is a pure beta-emitter with a relatively limited effective range and short half-life that helps focus the radiation and minimize its spread. Candidates for RE are initially examined by hepatic angiogram to identify and map the hepatic arterial system, and at that time, a mixture of albumin particles is delivered via the hepatic artery to simulate microspheres. After, single-photon emission computed tomography (CT) gamma imaging is used to detect possible shunting of the albumin particles into gastrointestinal or pulmonary vasculature.

### **Unresectable Primary Hepatocellular Carcinoma**

The majority of patients with HCC present with unresectable disease, and treatment options are limited secondary to the chemoresistance of HCC and the intolerance of normal liver parenchyma to tumoricidal radiation doses. Results of 2 randomized controlled trials (RCTs) have shown a survival benefit using transarterial chemoembolization (TACE) therapy versus supportive care in patients with unresectable HCC. In one study, patients were randomly assigned to TACE, transarterial embolization (TAE), or supportive care. One-year survival rates for TACE, TAE, and supportive care were 82%, 75%, and 63%, respectively, and 2-year survival rates were 63%, 50%, and 27%, respectively. A recent multicenter, randomized, double-blind placebo controlled Phase III trial that enrolled 602 patients with advanced HCC randomly assigned patients to receive sorafenib versus placebo. Overall survival (OS) was significantly longer in the sorafenib group compared with placebo (10.7 versus 7.9 months, respectively; hazard ratio [HR] for sorafenib: 0.69;  $p < 0.001$ ).

### **Unresectable Intrahepatic Cholangiocarcinoma**

Cholangiocarcinomas are tumors that arise from the epithelium of the bile duct and are separated into intrahepatic and extrahepatic types. Intrahepatic cholangiocarcinomas appear in the hepatic parenchyma and are also known as peripheral cholangiocarcinomas. Resection is the only treatment with the potential for cure and 5-year survival rates have been in the range of 20% to 43%. Patients with unresectable



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

disease may select among fluoropyrimidine-based or gemcitabine-based chemotherapy, fluoropyrimidine chemoradiation or best supportive care.

### **Unresectable Metastatic Colorectal Carcinoma**

Fifty to sixty percent of patients with colorectal carcinoma (CRC) will develop metastases, either synchronously or metachronously. Select patients with liver-only metastases that are surgically resectable can be cured, with some reports showing 5-year survival rates exceeding 50%. Emphasis on treating these patients with potentially curable disease is on complete removal of all tumor with negative surgical margins. The majority of patients diagnosed with metastatic colorectal disease are initially classified as having unresectable disease. In patients with metastatic disease limited to the liver, preoperative chemotherapy is sometimes used in an attempt to downsize the metastases in order to convert the metastatic lesions to a resectable status (conversion chemotherapy).

In patients with unresectable disease that cannot be converted to resectable disease, the primary treatment goal is palliative, with survival benefit shown with both second and third-line systemic chemotherapy. Recent advances in chemotherapy, including oxaliplatin, irinotecan and targeted antibodies like cetuximab, have doubled the median survival in this population from less than 1 year to more than 2 years. Palliative chemotherapy by combined systemic and hepatic arterial infusion (HAI) may increase disease-free (DF) intervals for patients with unresectable hepatic metastases from CRC.

Radiofrequency ablation (RFA) has been shown to be inferior to resection in local recurrence rates, and 5-year OS and is generally reserved for patients with potentially resectable disease that cannot be completely resected due to patient comorbidities, location of metastases (i.e., adjacent to a major vessel), or an estimate of inadequate liver reserve following resection. Radiofrequency ablation is generally recommended to be used with the goal of complete resection with curative intent. The role of local (liver-directed) therapy (including RE, chemoembolization, and conformal radiation therapy) in debulking unresectable metastatic disease remains controversial.

### **Unresectable Metastatic Neuroendocrine Tumors**

Neuroendocrine tumors are an uncommon, heterogeneous group of mostly slow-growing, hormone-secreting malignancies, with an average patient age of 60 years. Primary neuroendocrine tumors vary in location, but most are either carcinoids (which most commonly arise in the midgut) or pancreatic islet cells. Carcinoid tumors, particularly if they metastasize to the liver, can result in excessive vasoactive amine secretion including serotonin and are commonly associated with the carcinoid syndrome (diarrhea, flush, bronchoconstriction, and right valvular heart failure).

Although they are considered to be indolent tumors, at the time of diagnosis, up to 75% of patients have liver metastases, and with metastases to the liver, 5-year survival rates are less than 20%. Surgical resection of the metastases is considered the only curative option; however, less than 10% of patients are eligible for resection, as most patients have diffuse, multiple lesions.

Conventional therapy is largely considered to be palliative supportive care, to control, eradicate, or debulk hepatic metastases, often to palliate carcinoid syndrome or local pain from liver capsular stretching.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

Therapies for unresectable metastatic neuroendocrine tumors include medical (somatostatin analogs like octreotide), systemic chemotherapy, ablation (radiofrequency or cryotherapy), TAE or TACE, or radiation. Although patients often achieve symptom relief with octreotide, the disease eventually becomes refractory, with a median duration of symptom relief of approximately 13 months, with no known effect on survival. Systemic chemotherapy for these tumors has shown modest response rates of limited duration, is better for pancreatic neuroendocrine tumors compared to carcinoids, and is frequently associated with significant toxicity. Chemoembolization has shown response rates of nearly 80%, but the effect is of short duration and a survival benefit has not been demonstrated.

### **Miscellaneous Metastatic Tumors**

Small case reports have been published on the use of RE in many other types of cancer with metastases, including breast, head, and neck (including parotid gland), pancreaticobiliary, anal, thymic, thyroid, endometrial, lung, kidney, gastric, small bowel, esophageal, ovarian, cervical, prostatic, bladder, and for melanoma, sarcoma, and lymphoma.

### **FDA or Other Governmental Regulatory Approval**

U.S. Food and Drug Administration (FDA)

Currently, two commercial forms of yttrium-90 microspheres are available: a glass sphere, TheraSphere<sup>®†</sup> (MDS Nordion, Inc., Ontario, Canada) and a resin sphere, SIR-Spheres<sup>®†</sup> (Sirtex Medical Limited; Lake Forest, IL). Noncommercial forms are mostly used outside the U.S. While the commercial products use the same radioisotope (yttrium-90) and have the same target dose (100Gy), they differ in microsphere size profile, base material (i.e., resin vs. glass), and size of commercially available doses. These physical characteristics of the active and inactive ingredients affect the flow of microspheres during injection, their retention at the tumor site, spread outside the therapeutic target region, and dosimetry calculations. Note also that the FDA granted premarket approval of SIR-Spheres for use in combination with 5-fluorouridine (5-FU) chemotherapy by HAI to treat unresectable hepatic metastases from CRC. In contrast, TheraSphere was approved by humanitarian device exemption (HDE) for use as monotherapy to treat unresectable HCC. In January 2007, this HDE was expanded to include patients with HCC who have partial or branch portal vein thrombosis (PVT). For these reasons, results obtained with one product do not necessarily apply to other commercial (or noncommercial) products.

### **Rationale/Source**

#### **Unresectable Primary Hepatocellular Carcinoma**

Salem and colleagues (2010) reported the results of a single-center, prospective, longitudinal cohort study of 291 patients with HCC treated between January 2004 and December 2008. The patient population was heterogeneous and included patients with portal vein thromboses (43%), advanced disease and extrahepatic metastases (16%), which are usually exclusionary criteria for studies using locoregional therapy. Data were collected prospectively and included toxicity, imaging, and survival outcomes. Patients were staged by Child Pugh scores. Eighty seven percent of patients had received no prior therapy. A total of 526 treatments were administered (mean, 1.8; range 1-5). Scans were performed 4-6 weeks after each treatment and then at 2-3 month intervals once all disease was treated. Median follow-up time was 30.9 months. Imaging follow-up was available in 273 patients, with an average of 4.3 scans per patient. By World Health Organization (WHO) criteria, response rates were 42%; by European Association for the Study of



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

the Liver (EASL) criteria, 57%, with 23% complete response (CR) and 34% partial response (PR). Response rates were better in patients with Child Pugh A disease (WHO, 49%; EASL 66%) than those with Child Pugh B disease (WHO, 36%; EASL 51%), and WHO response rates varied by baseline largest tumor size: smaller than 5cm, 44%; 5-10cm, 42%; and larger than 10cm, 33%. Survival for patients with Child Pugh disease A and B was 17.2 months and 7.7 months, respectively ( $p = 0.002$ ). The authors concluded that patients with Child Pugh A disease, with or without portal vein thrombosis, benefitted most from the treatment but that the role of yttrium-90 in certain patients with HCC requires further exploration, including controlled studies comparing yttrium-90 with alternative locoregional therapies (RFA and TACE) and yttrium-90 in various combinations with systemic targeted therapies in advanced disease.

Carr and colleagues (2010) reported on a consecutive series of patients with HCC who were seen at a single medical center and who were not candidates for surgical resection. Patients either received conventional cisplatin-TACE between the years 1992 and 2000 ( $n = 691$ ), yttrium-90 microspheres between 2000 and 2005 ( $n = 99$ ), or no treatment ( $n = 142$ ). Median OS for the yttrium-90 group versus the TACE group was 11.5 months [95% confidence interval [CI]: 8-16 months] versus 8.5 months [95% CI: 8-10 months], respectively ( $p < 0.05$ ). Untreated patients had a median survival of 2 months. Although the authors felt there was a slight selection bias toward milder disease in the yttrium-90 group, they concluded that yttrium-90 and TACE appear to be equivalent regional therapies for patients with unresectable, nonmetastatic HCC.

Vente and colleagues (2009) conducted a meta-analysis on tumor response and survival in patients who received yttrium-90 glass or resin microsphere RE for the treatment of primary liver cancer (HCC) or metastases from CRC. (See below under unresectable metastatic CRC section for the data from the meta-analysis as pertains to that disease.) Included studies were from 1986 onward. Articles written in a language other than English or German were excluded, as were articles that did not present tumor response measured by CT scans or that did not present data on median survival times. To allow comparability of results with regard to tumor response, the category of "any response" was introduced, and included CR, PR, and stable disease (SD). Overall tumor response could only be assessed as any response because response categories were not uniformly defined in the analyzed studies.

In 14 articles, clinical data were presented on tumor response and survival for 425 patients with HCC who had received yttrium-90 RE. Treatment with resin microspheres was associated with a significantly higher proportion of any response than glass microsphere treatment (0.89 vs. 0.78, respectively;  $p = 0.02$ ). Median survival was reported in 7 studies in which survival time was defined as survival from microsphere treatment or from diagnosis or recurrence of HCC. Median survival from microsphere treatment varied between 7.1 and 21.0 months, and median survival from diagnosis or recurrence was 9.4–24.0 months.

The authors of the meta-analysis concluded that yttrium-90 RE is associated with high response rates, both in salvage and first-line settings, but that the true impact on survival will only become known after publication of several ongoing and/or to-be-initiated Phase III studies, as well as the results of trials in which yttrium-90 RE and modern chemotherapy agents are combined with novel biologic agents.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

Lewandowski and colleagues (2009) compared RE with chemoembolization in the efficacy of downstaging 86 patients with HCC from stage T3 to T2 (potentially making patients liver transplant candidates). Patients were treated with either RE using yttrium-90 microspheres (n = 43) or TACE (n = 43). Median tumor size was similar between the 2 treatment groups (5.7 and 5.6cm, for TACE vs.RE, respectively.) Partial response rates were 61% versus 37% for RE vs. TACE, respectively, with downstaging from T3 to T2 in 58% of patients treated with RE versus 31% with TACE ( $p < 0.05$ ).

A comparison of tumor response and survival among subgroups of patients with and without PVT was reported by Kulik and colleagues in 2008. Thirty-four percent of this Phase II open-label cohort of 108 unresectable HCC patients treated with TheraSphere had had either branch or main PVT. At 6 months, WHO criteria PR was observed in 42.2% of the overall cohort and in 34% and 66% of those with and without PVT, respectively. Kaplan Meier survival was statistically longer in the PVT-free group (467 days) than the branch (304 days) and main PVT (133.5 days) groups. At baseline, the PVT groups had higher tumor burden, Okuda stage, pretreatment bilirubin concentrations, and proportion of patients with portal hypertension than the non-PVT groups. Adverse events for the PVT groups were presented among those with and without baseline cirrhosis. Cirrhotic patients with main PVT were more likely than those without PVT to have worsening of baseline ascites (55% and 15%, respectively) with yttrium-90 microsphere treatment; no difference was seen among those without cirrhosis, although the numbers were small.

A large single series was reported by Salem and colleagues in 2002 that described treating approximately 300 patients with liver carcinoma with SIRT under an HDE at 8 unnamed institutions. The report provided no additional details on baseline characteristics of the patients and did not specify inclusion or exclusion criteria for treatment. Investigators only reported outcomes for a cohort of 54 HCC patients with Okuda stage I and II (median survival: 23 and 11 months, respectively; OS at 1 year: 68% and 37%, respectively).

### **Intrahepatic Cholangiocarcinoma**

Cholangiocarcinomas originate in the epithelium of the bile duct. Four case series on use of RE in ICC are summarized here.

A study by Hoffman et al. of RE with yttrium-90 resin microspheres included 24 patients with nonresectable chemorefractory intrahepatic ICC and no extrahepatic disease. The mean age of the sample was 65.2 years and the sample was 45.5% female. Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 51.5%, 1 in 21.2% and 2 in 27.3%. Previous therapy included chemotherapy in 78.8%, surgery in 36.4%, TACE in 9.1%, RFA in 5.1% and EBRT in 3.0%. Tumor response was assessed by RECIST criteria. A CR was seen in 0%, PR in 36.4%, SD in 51.5% and progressive disease (PD) in 15.2%. Follow-up ranged between 3.1 and 44 months (median: 10 months). Median OS was 22 months and median time to progression was 9.8 months. Favorable subgroups with respect to survival included those with ECOG performance status of 0, tumor burden as percentage of liver volume of 25% or less, response by CA-19-9 criterion and RECIST PR. The same subgroups except those with a CA-19-9 response had favorable time to progression results. Data were collected retrospectively and no toxicity results were reported.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

A 2011 study by Haug et al. addressed 26 consecutive patients with unresectable ICC who underwent RE with yttrium-90 glass microspheres. All patients had a Karnofsky performance status of 60% or more. Mean age was 64.3 years, 31% had extrahepatic disease and 42% were female. Treatment given previously included chemotherapy in 65%, surgery in 28%, local therapy in 20% and none in 24%. Tumor response results according to RECIST criteria were: CR in 0%, PR in 22%, SD in 65% and PD in 13%. Median OS was 51 weeks and multivariate analysis found that a PR from quantitative interpretation of positron emission tomography was a significant independent predictor of survival. Authors found no cases of grade 3 toxicity in transaminases or bilirubin.

In 2010, Saxena et al. published results for 25 patients with unresectable ICC who received RE with yttrium-90 resin microspheres. Extrahepatic disease was present in 48%, mean age was 57 years and 48% of patients were female. Prior treatment included surgery in 40%, chemotherapy in 72%, RFA in 6.1% and EBRT in 3.0%. By RECIST tumor response criteria, CR was seen in 0%, PR in 24%, SD in 48% and PD in 20%. Follow-up was collected between 0.4 and 55 months (median: 8.1 months). In the entire group, median OS was 9.3 months. Among subgroups, longer survival duration was seen in patients with peripheral tumors and those with ECOG performance status of 0. The proportion of patients with both grade 3 albumin toxicity and grade 3 bilirubin toxicity was 8%. Grade 3 alkaline phosphatase toxicity was observed in 4%. One patient (4%) experienced duodenal ulcer due to malperfusion of yttrium-90 microspheres.

A study by Ibrahim and colleagues from 2008 reported results on RE with yttrium-90 glass microspheres among 24 patients with unresectable ICC. The group was 33% female and had a median age of 68 years. Extrahepatic disease was present in 33%. Eastern Cooperative Oncology Group performance status was 0 in 42%, 1 in 50% and 2 in 8%. Prior chemotherapy had been used in 29%. Using the WHO tumor response criteria, CR was observed in 0%, CR in 27%, SD in 68% and PD in 5%. Follow-up was collected over a median of 17.7 months and median OS was 14.9 months. Subgroups that had favorable survival results included those with ECOG performance status of 0, no previous chemotherapy and peripheral tumor. Grade 3 albumin toxicity was found in 17%, grade 3 bilirubin toxicity in 4% and 1 patient (4%) developed a duodenal ulcer.

### **Unresectable Metastatic Colorectal Carcinoma**

The literature for unresectable metastatic CRC to the liver and RE consists of 3 small randomized studies, a technology assessment, Cochrane review, meta-analysis, a retrospective matched-pair comparison, and case series.

The first randomized study was published by Gray and colleagues in 2001, and randomly assigned 74 patients with bilobar unresectable liver metastases to monthly HAI with 5-FUDR alone or with the same chemotherapy plus a single infusion of yttrium-90 microspheres. The investigators closed the study after entering 74 patients (n = 70 eligible for randomization). The original goal was 95 patients. Reasons cited for the early closure included: 1) increasing patient and physician reluctance to participate; 2) decision by the FDA to accept intermediate endpoints to support applications for premarket application approval; and 3) lack of funding to complete the study. The smaller study population was adequate to detect increases in response rate (from 20% to 55%) and median time to disease progression (by 32% from 4.5 months), with



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

80% power and 95% confidence, but lacked sufficient statistical power to detect changes in survival. To monitor responses to therapy, investigators serially measured serum levels of carcinoembryonic antigen (CEA) and estimated tumor cross-sectional area and volume from repeated CT scans read by physicians blinded to treatment assignment. They reported increased overall responses (complete plus partial) measured by area (44% vs. 18%,  $p = 0.01$ ; HAI plus SIRT vs. HAI, respectively) and volume (50% vs. 24%, respectively;  $p = 0.03$ ), or by serum CEA levels (72% vs. 47%, respectively;  $p = 0.004$ ). They also reported increased time to disease progression detected by increased area (9.7 vs. 15.9 months, respectively;  $p = 0.001$ ) or volume (7.6 vs. 12.0 months, respectively;  $p = 0.04$ ). However, there were no significant differences between treatment arms in actuarial survival rates ( $p = 0.18$  by log rank test) or in 11 quality-of-life measures. Treatment-related complications (grades 3–4) included 23 events in each arm (primarily changes in liver function tests). Nevertheless, investigators concluded that a “single injection of SIR-Spheres plus HAI is substantially more effective” than the same HAI regimen delivered alone.

Despite the investigators’ assertions, these results are inadequate to support their conclusions for the following reasons: 1) Accrual was halted early, leaving the study underpowered. 2) Although the study involved oversight by an institutional review board, the report suggests early closure was at the sole discretion of the principal investigator without independent review or prospectively designed data monitoring procedures and stopping rules. 3) While in this study, response rate and time to progression after SIRT plus HAI appeared superior to the same outcomes after HAI alone, results for the SIRT plus HAI group are within the range reported by other randomized trials of HAI in comparable patients. 4) Results of this study may reflect use of a shorter-than-standard duration of HAI therapy and are confounded by administration of nonprotocol chemotherapy before and after SIRT. 5) The reported increases in response rates and time to progression improved neither duration of survival nor quality of life.

The second randomized trial was a Phase II study published in 2004 by the same research group as the Phase III trial. The study involved 21 patients with advanced colorectal liver metastases; a total of 11 patients received SIR-Spheres plus systemic chemotherapy (fluorouracil and leucovorin), and 10 received the same systemic chemotherapy alone. While the time to PD was greater in those receiving combination therapy (18.6 versus 3.6 months, respectively;  $p < 0.0005$ ), the small size of the study limits any conclusions.

The third trial, a Phase III study, involved 46 patients and compared intravenous 5-fluorouracil (5-FU) to hepatic intra-arterial injection of yttrium-90 microspheres (SIR-Spheres) with intravenous 5-FU in CRC metastatic only to the liver and refractory to standard chemotherapy. The time to liver progression, the primary outcome, was significantly improved in the group receiving SIR-Spheres, 2.1 versus 5.5 months, respectively ( $p = 0.003$ ). However, there was no difference in the more important outcome of median survival; this was 7.3 and 10.0 months, respectively ( $p = 0.80$ ).

A draft technology assessment (2010) from the California Technology Assessment Forum (CTAF) assessed 25 studies on the use of RE and inoperable metastatic CRC to the liver, including the 2 previously described randomized studies, 1 small retrospective study comparing SIRT to chemoembolization ( $n = 36$ ), and 21 case series. The assessment concluded that the 3 comparative studies all used different control interventions and that the nonrandomized study did not show any convincing improvements over



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

chemoembolization. The author stated that the assessment showed it is feasible to deliver radiation therapy to liver metastases and achieve at least PR in a substantial portion of patients with relatively few serious adverse events and that the results of the 2 randomized studies were encouraging but not definitive, as the trials were very small, the response rates in the control groups were lower than expected, and the control groups were not given what is currently considered standard first-line chemotherapy for metastatic CRC. The assessment concluded that the use of SIRT for unresectable CRC did not meet any of the CTAF technology assessment criteria, with the exception of criterion number 1 (i.e., the technology has final approval from the appropriate government regulatory bodies).

A 2009 Cochrane review assessed the above-outlined RCTs. The authors concluded that there was a lack of evidence that SIRT improves survival or quality of life in patients with metastatic CRC, whether it is given alone or with chemotherapy, and that there is a need for well-designed, adequately powered Phase III trials assessing the effect of SIRT when used with modern combination chemotherapy regimens.

In the aforementioned 2009 meta-analysis by Vente et al., in a total of 19 eligible studies, 792 patients with metastatic CRC had undergone yttrium-90 RE. Included in the meta-analysis were the 2 randomized trials previously addressed in this section of the policy. Two covariates were included in the meta-regression model: 1) whether an older generation of cytostatic agents (5-FU/LV or floxuridine) or a newer generation (5-FU/LV plus oxaliplatin [FOLFOX] or 5-FU/LV plus irinotecan [FOLFIRI]) was used, and 2) whether yttrium-90 RE was given as salvage therapy or as first-line treatment with adjuvant chemotherapy. The specific cytostatic agent(s) that were used did not affect response ( $p = 0.96$ ). Tumor response to yttrium-90 RE was high, with any response rates of approximately 80% in a salvage setting, and more than 90% when used as first-line treatment as neoadjuvant to chemotherapy, regardless of the chemotherapy regimen used. Median survival after yttrium-90 RE, irrespective of differences in determinants (microspheres type, chemotherapy protocol, and salvage or first-line) varied from 6.7 to 17.0 months.

A single arm, open-label study was reported by Mulcahy and colleagues (2009) and involved 72 patients with unresectable hepatic colorectal metastases treated with yttrium-90 microspheres (TheraSphere). To determine response, 128 lesions were used. A PR rate using WHO criteria was noted in 29 of 72 patients (40.3%), and at the lesional level the response rate was 40.6% (PR rate 37.5%; CR rate 3.1%). Stable disease was observed in 44.5% of patients, and disease progression was found in 14.8% of patients. Median follow-up was 26.2 months. Median OS was 40.3 months (95% CI: 29.0–51.6 months) for all patients from the time of cancer diagnosis, 34.6 months (95% CI: 24.4–41.8 months) from the time liver metastases were diagnosed, and 14.5 months (95% CI: 9.6–21.9) from the time of yttrium-90 therapy. A substratification analysis was performed, and favorable prognostic factors that indicated a benefit from yttrium-90 therapy included an ECOG performance status of 0, a liver tumor burden of 25% or less, and the absence of extrahepatic disease. For the patients with an ECOG performance status of 0 at the time of yttrium-90 treatment, the overall median survival from the onset of liver metastases was 42.8 months, or a 5-year survival rate of 25.9%, which are comparable outcomes to survival data for patients treated with primary resection, chemotherapy followed by resection, or RFA.

Jakobs and colleagues retrospectively reviewed case files of patients with CRC liver metastases in whom chemotherapy had failed and who therefore received a single-session, whole-liver treatment with yttrium-90



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

RE (n = 41). Response was partial in 7 patients, 25 patients had SD, and 4 had PD. Median OS was 10.5 months. Median survivals for patients with PR, SD, and PD were 29.3 months, 10.9 months, and 4.3 months, respectively. No severe toxicities were observed.

Kennedy and colleagues reported results for use of resin microspheres in 208 patients with liver metastases from CRC who had failed or were not candidates for standard chemotherapy. There were no CRs but 35% PRs by C (as determined by a 50% decrease in one tumor measure at 12 weeks). Median survival was 10.5 months for responders but 4.5 months for nonresponders. The authors noted that the majority of patients died with persistent liver disease and had uncontrolled systemic metastases. No quality of life or functional status measures were reported. In addition, the authors noted that their report was a retrospective review with associated problems of a mixture of patients and a lack of a controlled treatment protocol.

A retrospective, matched-pair comparison of RE and best-supportive care (n = 29) versus best-supportive care alone (n > 500) for chemo-refractory, liver-dominant colorectal metastases showed prolongation of survival in the group of patients who received RE.

### **Unresectable Metastatic Neuroendocrine Tumors**

The data on the use of RE for unresectable liver metastases from neuroendocrine tumors include one open-label phase 2 study, retrospective reviews and case series.

In 2010, Cao and colleagues reported the outcomes of 58 patients with unresectable neuroendocrine liver metastases from 2 different hospitals treated with yttrium-90 microspheres (SIR-Spheres) from 2003 to 2008. Data were examined retrospectively from a database. Response was assessed with radiographic evidence before and after RE and measured by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Patients typically had a CT scan within 3 months of treatment and every 3 to 6 months until disease progression or death. Systemic chemotherapy was routinely given at 1 institution but not the other. Mean patient age at the time of RE was 61 (range: 29-84 years), and 67% of patients were men. Primary tumor site was variable and included small bowel, pancreas, colon, thyroid, lung, and unknown. Thirty-one patients underwent surgical resection of their primary tumor, which was classified as low-grade in 15, intermediate-grade in 7, and high-grade in 7. Forty-three percent of patients had extrahepatic metastatic disease at study entry. Prior therapies before RE included liver resection in 19 patients, TAE or TACE in 6, ablation or percutaneous ethanol injection in 10, previous chemotherapy in 20, concurrent chemotherapy in 34, and post-RE chemotherapy in 5 patients. Median follow-up was 21 months (range 1-61 months). Fifty-one patients were evaluable, and 6 achieved a CR, 14 a PR, 14 had SD, and 17 had disease progression. Overall survival rates at 1, 2, and 3 years were 86, 58, and 47%, respectively. Median survival was 36 months (range: 1-61 months). Prognostic factors for survival included extent of tumor involvement of the liver, radiographic response to treatment, presence of extrahepatic disease at the time of RE, histological grade of tumor, and whether patients were responders (vs. nonresponders) to RE. Factors that were not significant prognostic features included age, sex, ECOG status, and previous therapy.

King and colleagues reported outcomes in patients treated in a single-institution prospective study. Thirty-four patients with unresectable neuroendocrine liver metastases were given radioactive microspheres [SIR-



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

Spheres] and concomitant 7-day systemic infusion of 5-FU, between 2003 and 2005. Mean patient age was 61 years (range: 32-79 years), and 65% were men. Mean follow-up was 35.2 +/- 3.2 months. The mean interval from diagnosis of hepatic metastases and treatment with SIR therapy was 36.6 +/- 6.7 months. Primary tumor sites were variable and included bronchus (n = 1), thyroid (n = 2), gastrointestinal (n = 15), pancreas (n = 8), and unknown (n = 8). Subjective changes from baseline hormone symptoms were reported every 3 months. Twenty-four patients (71%) had, at baseline assessment, symptoms of carcinoid syndrome, including diarrhea, flushing, or rash. At 3 months, 18 of 33 patients (55%) reported improvement of symptoms, as did 16 of 32 (50%) at 6 months. Radiologic tumor response was observed in 50% of patients and included 6 CR (18%), and 11 PR (32%). Mean OS was 29.4 +/- 3.4 months.

Kennedy and colleagues conducted a retrospective review of 148 patients from 10 institutions with unresectable hepatic metastases from neuroendocrine tumors who received resin microspheres. All patients had completed treatment of the primary tumor and metastatic disease and were not excluded based on prior therapy. Total number of resin microsphere treatments was 185, with retreatment in 22.3 % of patients (19.6% received two treatments, and 2.7%, 3 treatments). All patients were followed with imaging studies at regular intervals to assess tumor response (using either WHO or RECIST criteria) until death, or they were censored if a different type of therapy was given after the microspheres. The male to female ratio was 49% to 51%, respectively, and median age was 58 years (range: 26-95 years). Median follow-up was 42 months. By imaging, response rates were SD 22.7%, PR 60.5%, CR 2.7%, and PD 4.9%. Hepatic and extrahepatic metastases contributed to death in the majority of patients, with 7% lost to follow-up. Median survival was 70 months. The authors conclude that RE can deliver high doses of radiation preferentially to hepatic metastases from neuroendocrine tumors with encouraging response rates by imaging and symptomatic improvement (although there were no data presented in the study regarding symptoms).

Rhee and colleagues reported the results of a multicenter, open label Phase II study to assess the safety and efficacy of RE, using glass or resin microspheres, in 42 patients with metastatic neuroendocrine liver disease who had failed prior treatment(s), including medical (e.g., octreotide), surgical resection, bland or chemoembolization, and RFA or cryoablation. Mean patient age was 58 +/- 12 years for glass and 61 +/- 11 years for resin microspheres. Response Evaluation Criteria in Solid Tumors criteria were used to assess tumor response, which showed 92% of glass patients and 94% of resin patients were partial responders or had SD at 6 months after treatment. Median survival was 22 and 28 months for glass and resin, respectively.

Additional case series in patients with treatment-refractory, unresectable neuroendocrine hepatic metastases have shown good tumor response and improvement in clinical symptoms with RE.

### Miscellaneous Tumors

Data on the use of RE in metastatic breast cancer is limited to the use of RE alone (i.e., not in combination with chemotherapy), and studies have been conducted either during a hiatus between lines of chemotherapy or in patients refractory to standard of care chemotherapy. Three studies have been published, and consist of small numbers of heterogeneous patients.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

A 2013 study by Cianni and colleagues included 52 women with chemotherapy-refractory breast cancer and inoperable liver metastases. RE treatment entailed yttrium-90 resin microspheres. The median age was reported as 57.5 years. ECOG performance status was 0 in 55.7%, 1 in 26.9% and 2 in 17.3%. Extrahepatic disease was present in 46.1%. Chemotherapy had been administered previously in all patients, surgery in 17.3%, TACE in 3.8% and RFA in 3.8%. Tumor response results by RECIST criteria were: CR in 0%, PR in 56%, SD in 35% and PD in 10%. Median OS was 11.5 months. Patients were retrospectively divided into two risk groups based on ECOG performance status, degree of liver tumor burden and whether extrahepatic disease was present. Median survival in the low-risk group was 14.3 months, significantly better than in the high-risk group (8.2 months). Grade 3 gastritis was seen in 2 patients (4%).

Haug et al. published a case series of 58 women with chemotherapy-refractory breast cancer and unresectable hepatic metastases. They received RE with yttrium-90 resin microspheres. The mean age was 58 years and all patients had a Karnofsky performance status of 60% or higher. Extrahepatic disease was present in 66%. Prior treatments were not mentioned. By RECIST criteria, a CR was seen in 0%, PR in 25.6%, SD in 62.8% and PD in 11.6%. Mean follow-up covered 27.5 weeks. The median OS for the sample was 47 weeks. Two indices derived from quantitative interpretation of positron emission tomography were significant predictors of survival. Bilirubin toxicity was at grade 3 in 3% and grade 4 in 2%. Transaminase toxicity was grade 3 in 5% and grade 4 in 2%.

Jakobs and colleagues reported on the safety and survival of 30 patients (29 women and 1 man) who underwent RE with resin microspheres in a single-session, whole-liver treatment. All patients had failed prior polychemotherapy regimens (including at least anthracyclines and taxanes, hormonal therapy, and trastuzumab, when applicable). Twenty-three patients had follow-up data. At median follow-up of 4.2 months, PR, SD, and PD was observed in 61%, 35%, and 4% of patients, respectively. Clinically significant toxicities were observed in 8 of 30 patients and included increasing liver enzymes and bilirubin levels, nausea and vomiting, gastric ulcers and ascites; 1 death was due to treatment-related hepatic toxicity. Median follow-up was 14.2 months, with a median OS of 11.7 months. Median survival of responders versus nonresponders was 23.6 and 5.7 months, respectively. Median survival of patients with and without extrahepatic disease was 9.6 versus 16 months, respectively.

Bangash and colleagues reported on the safety and efficacy of the use of RE with glass microspheres in 27 female patients with progressing liver metastases while on polychemotherapy. Seventeen patients received 20 left lobe of liver treatments, and 20 received 22 right lobe of liver treatments. At the 90-day follow-up CT, CR and PR was observed in 9 patients (39%), SD in 12 (52%), and PD in 2 (9%). Median survival for ECOG 0 versus 1-3 was 6.8 versus 2.6 months, respectively and for patients with tumor burden less than 25% versus greater than 25% was 9.4 and 2.0 months, respectively.

Hepatic metastases from breast cancer in 44 patients at 3 hospitals were retrospectively reviewed by Coldwell and colleagues. Patients had failed first-, second-, or third-line treatment for their primary tumor and were not candidates for RFA, TACE, resection, IMRT, or stereotactic radiotherapy. At 12 weeks, a PR (using WHO criteria, at least 50% reduction in the cross-product of the tumor dimensions) to SIR-Spheres was observed by CT in 47% of patients with recorded follow-up (82% of the total). Symptoms were reported



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

to improve, although no specifics were provided. There were no radiation-related liver failures observed and, at a median follow-up of 14 months, the cohort had not yet reached its expected median survival of 14 months.

Four studies have reported on use of RE in patients with hepatic metastases from melanoma. Three studies included only patients with ocular melanoma, and the fourth included patients with either ocular or cutaneous melanoma. Sample sizes ranged between 11 and 32 patients. Three studies excluded those with poor performance status. Median age was in the 50s for 3 studies and 61 in the fourth. One article did not describe any previous treatment and one described it incompletely. Three studies reported tumor response data, by RECIST criteria. Among 32 patients in the study by Gonsalves et al. (2011), one patient had a CR (3%), one had a PR, 18 patients had SD (56%) and 12 patients had PD (38%). In the study of 13 patients published by Klingenstein et al. (2013), none had a CR, 8 had a PR (62%), 2 had SD (15%) and 3 had PD (23%). Nine of 11 patients in the article by Kennedy et al. (2009) provided response data: one had CR, 6 had PR, 1 had SD and 1 had PD. Median survival in Gonsalves, Klingenstein, and Kennedy were 10.0 months, 19 months and not yet reached, respectively. Gonsalves reported 4 patients (12.5%) with grade 3-4 liver toxicity. Klingenstein observed one patient with marked hepatomegaly. Kennedy described one grade 3 gastric ulcer. The fourth study (Piduru et al., 2012, n = 12) did not include any toxicity data.

Data on the use of RE in other tumors metastatic to the liver are limited and composed of patient numbers too small to draw meaningful conclusions.

### **2010 National Comprehensive Cancer Network (NCCN) Guidelines**

#### Primary Hepatocellular Carcinoma

Guidelines recommend that patients with unresectable/inoperable disease who are eligible to undergo embolization therapy and have tumor lesions larger than 5cm should be treated using arterial embolic approaches (chemoembolization, bland embolization, or RE), whereas patients with lesions 3-5cm can be considered for combination therapy with ablation and arterial embolization, and tumors of or less than 3cm should be treated with ablation (all category 2A) but that randomized, controlled studies on the use of RE therapy in the treatment of patients with HCC are needed.

#### Primary Cholangiocarcinoma

Recommendations for unresectable ICC include chemotherapy, chemoradiation and supportive care. The use of RE is addressed only for resectable disease.

#### Metastatic Colorectal Cancer

Use of arterial-directed therapies such as RE in highly select patients remains a category 3 recommendation based on the relatively limited amount of evidence and different institutional practices.

#### Metastatic Neuroendocrine Tumors

For unresectable liver metastases (carcinoid or islet cell), recommendations include hepatic regional therapy with (category 2B).



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

## Metastatic Breast Cancer

Current recommendations do not address the use of RE in the treatment of metastatic breast cancer.

## Metastatic Melanoma

Current recommendations do not address the use of RE in the treatment of metastatic melanoma.

## **Radioembolization Brachytherapy Oncology Consortium**

Members met as an independent group of experts in interventional radiology, radiation oncology, nuclear medicine, medical oncology, and surgical oncology. Using level 2A evidence (panel consensus with low-level evidence), 14 recommendations were made. Conclusions included that there was sufficient evidence to support the safety and efficacy of yttrium-90 microsphere therapy and that its use requires multidisciplinary management, adequate patient selection, and meticulous angiographic technique. They also stated that the initiation of clinical trials was necessary to further define the role of yttrium-90 microsphere therapy in relation to other currently available therapies.

## **National Cancer Institute (NCI) Clinical Trial Database (PDQ®)†**

The following is a list of ongoing comparative studies using RE for primary or metastatic liver tumors.

### Unresectable Hepatocellular Carcinoma

Four RCTs comparing yttrium-90 RE with TACE have either not been published or have not yet been completed. NCT00109954 enrolled a target of 120 patients with advanced unresectable HCC. The study start date was February 2005 and the current trial status is unknown. NCT00867750 began in March 2006, enrolling 28 patients with unresectable HCC and was completed in June 2011. The start date of NCT00956930 was August 2009, with an expected completion date of August 2016. NCT01381211 began in September 2011, enrolling a target of 140 patients with intermediate HCC.

Two RCTs compare sorafenib with yttrium-90 RE. NCT01135056 had a start date of July 2010. It aims to enroll 360 patients with locally advanced HCC and close in July 2015. NCT01482442 started in December 2011 and is scheduled to finish March 2015. The target sample size of 400 will include patients with advanced HCC not eligible for resection, transplantation and RFA.

In two RCTs, sorafenib is included in both treatment arms. NCT01556490 began in March 2012, comparing sorafenib alone with sorafenib plus RE in patients with unresectable HCC. It aims to enroll 400 patients and mark completion by October 2016. NCT01126645 compares RFA plus sorafenib with RE plus sorafenib among patients with inoperable HCC. It began in December 2010 and is expected to finish in February 2014.

NCT00846131 uses RE in both arms and one arm combines it with sorafenib. Included patients have pre-transplant HCC with the intention of downstaging/bridging. With a target enrollment of 40, the trial started in February 2009 and is scheduled for completion in February 2014.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
Original Effective Date: 02/23/2004  
Current Effective Date: 10/16/2013

### Metastatic Colorectal Cancer

Four RCTs that have not been published or completed compare anticancer agents to those same agents plus RE. NCT00724503 assesses the effect of adding SIRT, using SIR-Spheres microspheres, to a standard chemotherapy regimen of FOLFOX as first-line therapy in patients with nonresectable liver metastases from primary colorectal adenocarcinoma (SIRFLOX). The primary outcome measure is progression-free survival. Trial status is active, with estimated enrollment of 450 and estimated study completion date of December 2012.

NCT01483027 began in January 2012 as a comparison between standard of care second-line chemotherapy versus that chemotherapy plus TheraSphere RE. Target enrollment is 360 patients with liver metastases from CRC that progressed after first-line therapy. Completion is expected in September 2016.

NCT01721954 is a comparison of the FOLFOX6m chemotherapy regimen +/- bevacizumab versus FOLFOX6m chemotherapy regimen +/- bevacizumab plus SirSphere RE. A target sample of 200 patients have liver metastases from CRC not treatable by surgery or local ablation. The start date is February 2013 and completion is expected in January 2014.

ISRCTN83867919 is an open-label randomized Phase III trial of 5-FU, oxaliplatin, and folinic acid +/- interventional RE as first-line treatment for patients with unresectable liver only or liver-predominant metastatic CRC (FOXFIRE). The primary outcome measure is OS. Target number of participants is 490 with an anticipated end date of January 2014.

One RCT completed in 2010 but not yet published compared 5-FU chemotherapy with SIR-Sphere RE. The patient population consists of patients who had liver metastases and were refractory to standard chemotherapy.

### **Summary**

- Hepatocellular carcinoma: Studies have demonstrated that RE is comparable to TACE (which is considered to be therapy of choice) for patients with unresectable HCC in terms of tumor response and OS. Disadvantages of TACE include the necessity of multiple treatment sessions and hospitalization, its contraindication in patients with PVT, and its poorer tolerance by patients.
- Intrahepatic cholangiocarcinoma: To date, studies on use of RE in patients with ICC consist of small case series. No studies have been published comparing RE to other treatments such as chemotherapy or chemoradiation. Available studies varied with respect to patient characteristics, particularly presence of extrahepatic disease, previous therapy and performance status.
- Metastatic colorectal cancer: A major cause of morbidity and mortality in patients with colorectal disease metastatic to the liver is liver failure, as this disease tends to progress to diffuse, liver-dominant involvement. Therefore, the use of RE to decrease tumor bulk and/or halt the time to tumor progression and liver failure, may lead to prolonged progression free and OS in patients with no other treatment options (i.e., those with chemotherapy refractory liver-dominant disease). Other uses include palliation of symptoms from tumor bulk. Two Phase III trials are currently underway that compare first-line chemotherapy with and without RE in patients with metastatic CRC.



# Blue Cross Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

- Metastatic neuroendocrine tumors: Studies have included heterogeneous patient populations, and interpretation of survival data using RE is difficult. One study reports relief of symptoms from carcinoid syndrome in a proportion of patients. Surgical debulking of liver metastases has shown palliation of hormonal symptoms; debulking by RE may lead to symptom relief in some patients.
- Miscellaneous: Three studies on the use of RE in metastatic breast cancer to the liver have shown promising initial results; however, the data are limited and the studies have been small and composed of heterogeneous patients. The use of RE in other tumors metastatic to the liver is too limited to draw meaningful conclusions; this use is considered investigational.

## References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Radioembolization for Primary and Metastatic Tumors of the Liver", 8.01.43, 3:2013.
2. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. *Lancet* 2002; 359(9319):1734-9.
3. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; 35(5):1164-71.
4. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). *J Clin Oncol* 2007; 25(18S):LBA1.
5. National Cancer Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers (V.2.2012). 2012. [http://www.nccn.org/professionals/physician\\_gls/PDF/hepatobiliary.pdf](http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf).
6. Tice J. Selective internal radiation therapy or radioembolization for inoperable liver metastases from colorectal cancer. *California Technology Assessment Forum*. 2010. <http://www.ctaf.org/UserFiles/File/2010%20Feb/SIRT%20radioembolization%20final%20draft2.pdf>.
7. National Cancer Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer (V.3.2012). 2012. [http://www.nccn.org/professionals/physician\\_gls/PDF/colon.pdf](http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf).
8. King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer* 2008; 113(5):921-9.
9. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. *Cancer J* 2010; 16(2):163-75.
10. Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; 138(1):52-64.
11. Carr BI, Kondragunta V, Buch SC et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. *Cancer* 2010; 116(5):1305-14.
12. Vente MA, Wondergem M, van der Tweel I et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *Eur Radiol* 2009; 19(4):951-9.
13. Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant* 2009; 9(8):1920-8.
14. Kulik LM, Carr BI, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology* 2008; 47(1-Jan):71-81.
15. Salem R, Thurston KG, Carr BI et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. *J Vasc Interv Radiol* 2002; 13(9 pt 2):S223-9.
16. Hoffmann RT, Paprottka PM, Schon A et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. *Cardiovasc Intervent Radiol* 2012; 35(1):105-16.
17. Haug AR, Heinemann V, Bruns CJ et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. *Eur J Nucl Med Mol Imaging* 2011; 38(6):1037-45.
18. Saxena A, Bester L, Chua TC et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. *Ann Surg Oncol* 2010; 17(2):484-91.
19. Ibrahim SM, Mulcahy MF, Lewandowski RJ et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. *Cancer* 2008; 113(8):2119-28.
20. Gray B, Van Hazel G, Hope M et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol* 2001; 12(12):1711-20.

©2013 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

21. Van HG, Blackwell A, Anderson J et al. Randomized phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol* 2004; 88(2):78-85.
22. Hendlisz A, Van den Eynde M, Peeters M et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol* 2010; 28(23):3687-94.
23. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. *Cochrane Database Syst Rev* 2009; (4):CD007045.
24. Mulcahy MF, Lewandowski RJ, Ibrahim SM et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. *Cancer* 2009; 115(9):1849-58.
25. Jakobs TF, Hoffmann RT, Dehm K et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. *J Vasc Interv Radiol* 2008; 19(8):1187-95.
26. Kennedy AS, Coldwell D, Nutting C et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. *Int J Radiat Oncol Biol Phys* 2006; 65(2):412-25.
27. Seidensticker R, Denecke T, Kraus P et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. *Cardiovasc Intervent Radiol* 2012; 35(5):1066-73.
28. Cao CQ, Yan TD, Bester L et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. *Br J Surg* 2010; 97(4):537-43.
29. Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol* 2008; 31(3):271-9.
30. Rhee TK, Lewandowski RJ, Liu DM et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. *Ann Surg* 2008; 247(6):1029-35.
31. Memon K, Lewandowski RJ, Mulcahy MF et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. *Int J Radiat Oncol Biol Phys* 2012; 83(3):887-94.
32. Paprottka PM, Hoffmann RT, Haug A et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. *Cardiovasc Intervent Radiol* 2012; 35(2):334-42.
33. Cianni R, Pelle G, Notarianni E et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. *Eur Radiol* 2013; 23(1):182-9.
34. Haug AR, Tiega Donfack BP, Trumm C et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. *J Nucl Med* 2012; 53(3):371-7.
35. Jakobs TF, Hoffmann RT, Fischer T et al. Radioembolization in patients with hepatic metastases from breast cancer. *J Vasc Interv Radiol* 2008; 19(5):683-90.
36. Bangash AK, Atassi B, Kaklamani V et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. *J Vasc Interv Radiol* 2007; 18(5):621-8.
37. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. *Int J Radiat Oncol Biol Phys* 2007; 69(3):800-4.
38. Gonsalves CF, Eschelmann DJ, Sullivan KL et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. *AJR Am J Roentgenol* 2011; 196(2):468-73.
39. Kennedy AS, Nutting C, Jakobs T et al. A first report of radioembolization for hepatic metastases from ocular melanoma. *Cancer Invest* 2009; 27(6):682-90.
40. Klingenstein A, Haug AR, Zech CJ et al. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. *Cardiovasc Intervent Radiol* 2013; 36(1):158-65.
41. Piduru SM, Schuster DM, Barron BJ et al. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. *J Vasc Interv Radiol* 2012; 23(7):943-8.
42. National Cancer Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Neuroendocrine Tumors (V.1.2012). . 2012. [http://www.nccn.org/professionals/physician\\_gls/PDF/neuroendocrine.pdf](http://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf).
43. National Cancer Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer (V.3.2012). . 2012. [http://www.nccn.org/professionals/physician\\_gls/PDF/breast.pdf](http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf).
44. National Cancer Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Melanoma (V.2.2013). 2013. [http://www.nccn.org/professionals/physician\\_gls/PDF/melanoma.pdf](http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf).
45. Kennedy A, Nag S, Salem R et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys* 2007; 68(1):13-23.

©2013 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Blue Cross Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110  
 Original Effective Date: 02/23/2004  
 Current Effective Date: 10/16/2013

### Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2012 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	37243 (New code added 01/01/2014), 75894, 77399, 77778, 79445 (Code 37204 was deleted effective 01/01/2014)
HCPCS	A9543, S2095
ICD-9 Diagnosis	155.0, 209.72
ICD-9 Procedure	No code

### Policy History

Original Effective Date: 02/23/2004  
 Current Effective Date: 10/16/2013

01/31/2004 Medical Director review.  
 02/17/2004 Medical Policy Committee review.  
 02/23/2004 Managed Care Advisory Council approval.  
 02/01/2006 Medical Director review  
 02/15/2006 Medical Policy Committee review. Format revisions, Rationale/Source.  
 02/23/2006 Quality Care Advisory Council approval.  
 07/07/2006 Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.  
 03/14/2007 Medical Director review.  
 03/21/2007 Medical Policy Committee approval. Coverage eligibility unchanged.  
 04/02/2009 Medical Director review.  
 04/15/2009 Medical Policy Committee approval. Added "(SIRT)" to title. Revised investigational statement from "Based on review of available data, the Company considers the use of internal radiation therapy for all indications including, but not limited to, the treatment of primary or metastatic tumors of the liver, to be **investigational**." to "Based on review of available data, the Company considers selective internal radiation therapy using intra-arterial injection of radiolabeled microspheres to treat primary or metastatic liver tumors to be **investigational**.\*" Coverage eligibility unchanged.

©2013 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

## Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

09/09/2010	Medical Policy Committee review.
09/15/2010	Medical Policy Implementation Committee approval. policy statement and title (“selective internal radiation therapy” changed to “radioembolization”). Policy statements changed to indicate that selective cases of hepatocellular carcinoma and metastatic neuroendocrine tumors may be considered medically necessary. Title changed to reflect current procedure name.
04/07/2011	Medical Policy Committee review.
04/13/2011	Medical Policy Implementation Committee approval. Added that “radioembolization to treat unresectable hepatic metastases from colorectal cancer that are both progressive and diffuse, in patients with liver-dominant disease who are refractory to chemotherapy or are not candidates for chemotherapy is eligible for coverage.
04/05/2012	Medical Policy Committee review.
04/18/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/11/2012	Medical Policy Committee review.
10/31/2012	Medical Policy Implementation Committee approval. Investigational statement for unresectable hepatic metastases from colorectal carcinoma removed, since it is eligible for coverage.
10/03/2013	Medical Policy Committee review
10/16/2013	Medical Policy Implementation Committee approval. New investigational statement on intrahepatic cholangiocarcinoma added.
03/25/2014	Coding update due to codes added and deleted from policy
Next Scheduled Review Date:	10/2014

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
  1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
  2. credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
  3. reference to federal regulations.

\*\*Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. in accordance with nationally accepted standards of medical practice;
- B. clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

©2013 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioembolization for Primary and Metastatic Tumors of the Liver

Policy # 00110

Original Effective Date: 02/23/2004

Current Effective Date: 10/16/2013

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.